The use of antithrombotic drugs in older XXXX .

@entity1 @entity64 @entity455 @entity101 @entity548 @entity146 @entity1397 @entity117 @entity1229 @entity1151 @entity1150 @entity1459 @entity4905 @entity56 @entity955 @entity1211 @entity583 @entity204 @entity130 @entity385
Older individuals (subjects aged >65 years) largely contribute to the percentage @entity204 due to @entity583 ( @entity583 ) and @entity64 . The incidence of @entity1211 ( @entity1211 ) is also higher >65 years old @entity1 . However, the risk of @entity548 complications in patients on antithrombotic drugs increases with age and with clinical conditions, as @entity146 , @entity130 , @entity101 , poor compliance with medications, common in the elderly. Thus the risk-benefit ratio of antithrombotics should be carefully evaluated in older individuals. To prevent the risk and the recurrence of @entity385 and @entity583 in the older @entity1 with stable/ @entity1459 , @entity583 , @entity4905 / @entity64 or peripheral @entity455 , antiplatelet drugs are of choice. @entity117 is the most widely used antiplatelet drug. @entity1397 is safer and more effective than @entity117 in this respect. The combination of heparin and @entity117 is the treatment of choice for @entity1459 and @entity583 , also in the elderly. Low molecular weight heparins (LMWHs) proved to be as effective as standard heparin in this indication. In the absence of contraindications, thrombolysis for treatment of @entity583 may be considered in the elderly. For the treatment of @entity1211 ( @entity1211 ), intravenous standard heparin, subcutaneous standard heparin or LMWHs are effective. Because of the limited risk/benefit ratio, thrombolytic agents are not recommended for treating @entity1150 ( @entity1150 ) in the elderly. They should be limited to young @entity1 and to @entity1 with massive @entity1151 ( @entity1151 ). For chronic treatment of @entity1211 , @entity1229 is the treatment of choice (INR 2.0-3.0), also in the elderly. Because of @entity56 to oral anticoagulants, lower dosages of @entity1229 are needed in the old @entity1 . As to prophylaxis of @entity1211 in surgery, in subjects at low-moderate risk, or in medical @entity1 , low-dose heparin or low-dose LMWHs are effective. As to prophylaxis of @entity1211 in surgery in subjects at high risk, adjusted-dose heparin or high-dose LMWHs are recommended. Finally, as to prevention of @entity64 in @entity1 older than 75 with @entity955 ( @entity955 ), @entity1229 is of choice.
